Florida Sues Pfizer Over Claims It Hid Myocarditis and Miscarriage Risks as COVID Vaccine Sales Hit $80B

Florida sued Pfizer and CEO Albert Bourla, alleging misleading COVID-19 vaccine marketing and unfair practices. The state seeks injunctions, profit disgorgement, and penalties. Pfizer reported $85.81 billion in vaccine revenue from 2021 to 2023. The company denies wrongdoing, stating its claims are science-based.

Florida AG James Uthmeier sued Pfizer and CEO Albert Bourla, alleging misleading claims about COVID-19 vaccine safety and effectiveness. Pfizer denies the allegations, stating they lack merit.

Pfizer (PFE) reported positive Phase 2 data for tilrekimig, showing strong response rates and itch relief. Shares fell 1.23% to $28.17. Meanwhile, Florida's AG sued Pfizer and its CEO over alleged COVID-19 vaccine misstatements, seeking fines and injunctive relief. Pfizer disputes the claims, according to Reuters.

Florida's Attorney General has filed a lawsuit against Pfizer and its CEO, alleging misleading claims about the safety and effectiveness of its COVID-19 vaccine. The lawsuit seeks to hold the company accountable for its marketing and communications regarding the vaccine.

Florida's attorney general sued Pfizer and CEO Albert Bourla, alleging deceptive marketing of COVID-19 vaccines as safe, despite known risks like myocarditis. The state seeks fines and profit returns, citing $80 billion in revenue. Pfizer denies wrongdoing, asserting its statements were science-based.

Pfizer (NYSE:PFE) reported Phase 2 trial results for its eczema drug tilrekimig, showing significant skin clearance. The trial met its primary endpoint, with 62.5% of patients achieving EASI-75 in Stage 1 and 47.8%-61.0% in Stage 2. The drug also showed improvements in secondary endpoints and itch reduction. Tilrekimig was well-tolerated with no dose-dependent safety signals. PFE shares were down 1.23% at $28.17 at the time of publication.